Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTeam17 Regulatory News (TM17)

  • There is currently no data for TM17

Trading Update

29 Jan 2019 07:00

RNS Number : 3209O
Team17 Group PLC
29 January 2019
Ā 

29 January 2019

Ā 

Team17 Group plc

("Team17", the "Group" or the "Company")

Ā 

Trading update

Ā 

Team17, a global games label, creative partner and developer of independent ("indie") premium video games, provides an update for the year ended 31 December 2018.

Ā 

The Company is pleased to report it has continued to see strong sales momentum in the second half, particularly in the sales of third party titles such as Overcooked 2. The Company will therefore report revenues ahead of expectations and adjusted EBITDA at the upper end of market expectations.

Ā 

The Company's growing back catalogue portfolio has continued to perform well over the course of 2018, demonstrating the strength of the team's capabilities in life cycle management.

Ā 

Furthermore, the Company is pleased to see the quality of its games and people being recognised in the media and at leading industry events throughout 2018. The Company and Portfolio received over 130 Awards and Nominations in 2018, notably at the international gaming industry's flagship awards ceremony, The Game Awards, held in Los Angeles in December, where Overcooked 2 was awarded Best Family Game. Furthermore, Yoku's Island Express collected over 70 nominations or awards in the Industry's media roundup of 'Best of 2018' Games.

Ā 

The Company has a solid portfolio of game launches planned for 2019, including My Time at Portia, which exited Early Access on 15 January 2019 and launched on both Valve's Steam Store and the Epic Games store. The game has had an encouraging start and will be launching across additional platforms in Spring 2019. Genesis Alpha One will launch today on PlayStation 4, Xbox One and on PC, exclusively via the recently launched Epic Games store. The Escapists 2: Pocket Breakout, sequel to the Company's owned multi million unit selling Escapist franchise, will also make its debut on Android (Google Play & Amazon stores) and iOS (Apple store) on 31 January 2019.

Ā 

The Company will report its full year results for the year ended 31 December 2018 on Tuesday, 19 March 2019.

Ā 

Enquiries:

Ā 

Team17 Group plc

Debbie Bestwick MBE, Chief Executive Officer

Jo Jones, Chief Financial Officer

Ā 

via Vigo Communications

Ā 

GCA Altium (Nominated Adviser)

Adrian Reed / Paul Lines

Ā 

+44 (0)845 505 4343

Berenberg (Broker)

Chris Bowman / Toby Flaux / Marie-Agnes Stolberg

Ā 

+44 (0)20 3207 7800

Vigo Communications (Financial Public Relations)

Jeremy Garcia / Fiona Henson / Charlie Neish

team17@vigocomms.com

+44 (0)20 7390 0238

Ā 

Ā 

Ā 

Ā 

About Team17

Ā 

Founded in 1990, Team17 Group plc is a leading international premium video games label and creative partner for independent developers. The portfolio comprises over 100 games, including The Escapists, Genesis Alpha One, My Time At Portia, Overcooked, Yoku's Island Express, Yooka-Laylee, the Worms franchise and many more from developers around the world. Visit www.team17.com for more info.

Ā 

Ā 

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Ā 
END
Ā 
Ā 
TSTBPMFTMBITBIL
Date   Source Headline
23rd Jan 20257:00 amRNSTrading Update and Change of Company Name
15th Nov 202412:30 pmRNSIssue of Shares and Total Voting Rights
15th Nov 202410:00 amRNSEstablishment of New Option Plan, Grant of Options
7th Nov 20243:33 pmRNSDirector Dealing
6th Nov 20247:00 amRNSChange of Nomad & Directors Disclosures
1st Nov 20247:00 amRNSHoldings in Company
30th Oct 20247:00 amRNSBoard Change
24th Oct 20244:20 pmRNSHoldings in Company
14th Oct 20247:00 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSChange of Nominated Advisor
17th Sep 20247:00 amRNSHalf Year Results
11th Sep 20243:02 pmRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSHoldings in Company
4th Sep 20242:25 pmRNSHoldings in Company
28th Aug 20247:00 amRNSNotice of Results & Analyst/Investor Presentations
22nd Aug 20247:00 amRNSHoldings in Company
14th Aug 20244:15 pmRNSDirector/PDMR Shareholding
17th Jul 20247:00 amRNSTrading Update
11th Jul 20245:03 pmRNSDirector/PDMR Shareholding
9th Jul 20244:18 pmRNSDirector/PDMR Shareholding
19th Jun 202411:15 amRNSResult of AGM
13th Jun 20249:20 amRNSDirector/PDMR Shareholding
3rd Jun 20247:00 amRNSAppointment of Joint Corporate Broker
23rd May 202412:00 pmRNSPosting of Annual Report and Notice of AGM
13th May 20244:55 pmRNSDirector/PDMR Shareholding
16th Apr 20247:00 amRNSUnaudited Final Results 2023
12th Apr 20241:16 pmRNSDirector/PDMR Shareholding
11th Apr 20247:00 amRNSNotice of Analyst & Investor Meetings, FY Results
19th Mar 20243:29 pmRNSHoldings in Company
13th Mar 20248:30 amRNSDirector/PDMR Shareholding
1st Mar 20248:58 amRNSNotice of Results
14th Feb 20241:00 pmRNSDirector/PDMR Shareholding
13th Feb 20244:28 pmRNSDirector/PDMR Shareholding
1st Feb 20241:10 pmRNSHolding(s) in Company
29th Jan 20247:00 amRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading Update
19th Jan 20243:01 pmRNSHolding(s) in Company
12th Jan 20244:53 pmRNSHolding(s) in Company
12th Jan 20243:04 pmRNSHolding(s) in Company
11th Jan 20243:23 pmRNSDirector/PDMR Shareholding
14th Dec 20239:15 amRNSDirector/PDMR Shareholding
28th Nov 20237:00 amRNSDirector Dealings
27th Nov 20237:00 amRNSDirector Dealings
24th Nov 20237:00 amRNSTrading Update
15th Nov 20233:29 pmRNSHolding(s) in Company
13th Nov 20234:57 pmRNSDirector/PDMR Shareholding
30th Oct 20233:51 pmRNSHolding(s) in Company
18th Oct 202312:41 pmRNSHolding(s) in Company
11th Oct 20235:14 pmRNSDirector/PDMR Shareholding
21st Sep 20231:06 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.